Global Rollout of Affordable Rapid COVID-19 Tests: Traveler Information Summary
On 28 September 2020, the World Health Organization and partners in the Access to COVID-19 Tools (ACT) Accelerator announced agreements to make 120 million antigen-based rapid diagnostic tests (Ag RDTs) available to low- and middle-income countries (LMICs) over six months, at a ceiling price of US$5 per test.
Key points from the announcement
- Partners involved: WHO, Africa CDC, the Bill & Melinda Gates Foundation, CHAI, FIND, the Global Fund, and Unitaid.
- Manufacturers: Volume-guarantee agreements were signed with Abbott (Panbio COVID-19 Ag test) and SD Biosensor (STANDARD Q COVID-19 Ag test).
- Turnaround time: Results in approximately 15–30 minutes, versus hours or days for laboratory PCR (NAAT) testing.
- Financing: The Global Fund committed an initial US$50 million from its COVID-19 Response Mechanism, enabling purchase of at least 10 million tests through pooled procurement.
- Deployment: Unitaid and Africa CDC planned rollout in up to 20 African countries beginning October 2020, supporting the African Union's PACT initiative.
- Regulatory status: Several point-of-care antigen tests were under WHO Emergency Use Listing (EUL) review; the first EUL-approved Ag RDT was listed within eight months of viral sequencing.
- Stated use case: WHO guidance of 11 September 2020 described value where community transmission is widespread and PCR testing is unavailable or significantly delayed — for test-trace-isolate strategies, outbreak confirmation, screening, and trend monitoring.
- Target: The Diagnostics Pillar aimed to supply 500 million tests to LMICs within 12 months.
Relevance for international travelers
This announcement concerns procurement and public-health capacity, not individual travel requirements. It signals that point-of-care testing may become more widely accessible in destinations with limited laboratory infrastructure. Entry, transit, and exit testing rules are set by national authorities and airlines, not by WHO, and have changed substantially since 2020.
Pharmacist's note: As a pharmacist with a background in pharmaceutical sciences, I would emphasize that antigen rapid tests and molecular (PCR/NAAT) tests are not interchangeable in every context. Antigen assays generally offer lower analytical sensitivity, so performance depends heavily on viral load, timing relative to symptom onset, specimen collection quality, and local prevalence. A negative result does not definitively exclude infection, and a positive result is interpreted against the clinical and epidemiological picture. Travelers should verify which test type a destination or carrier accepts before departure, confirm that a chosen test is authorized in the relevant jurisdiction, and respect manufacturer storage and expiry conditions for self-tests carried in luggage. Any symptoms or test result should be discussed with a licensed clinician locally; this summary is public information only and is not medical advice or a treatment recommendation.
Source: WHO news release, 28 September 2020.